Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial,Epilepsia

当前位置： X-MOL 学术 › Epilepsia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial
Epilepsia ( IF 5.6 ) Pub Date : 2021-07-20 , DOI: 10.1111/epi.17000
Anup D Patel ₁ , Maria Mazurkiewicz-Bełdzińska ₂ , Richard F Chin ₃ , Antonio Gil-Nagel ₄ , Boudewijn Gunning ₅ , Jonathan J Halford ₆ , Wendy Mitchell ₇ , Michael Scott Perry ₈ , Elizabeth A Thiele ₉ , Arie Weinstock ₁₀ , Eduardo Dunayevich ₁₁ , Daniel Checketts ₁₂ , Orrin Devinsky ₁₃

Affiliation

Nationwide Children's Hospital, Columbus, Ohio, USA.
Department of Developmental Neurology, Medical University of Gdańsk, Gdańsk, Poland.
Muir Maxwell Epilepsy Centre, University of Edinburgh, Edinburgh, UK.
Neurology Department, Ruber Internacional Hospital, Madrid, Spain.
Stichting Epilepsie Instellingen Nederland, Zwolle, the Netherlands.
Department of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.
Keck School of Medicine, University of Southern California and Children's Hospital Los Angeles, Los Angeles, California, USA.
Cook Children's Medical Center, Fort Worth, Texas, USA.
Massachusetts General Hospital, Boston, Massachusetts, USA.
Oishei Children's Hospital, Buffalo, New York, USA.
Greenwich Biosciences, Carlsbad, California, USA.
GW Research Ltd., Cambridge, UK.
New York University Comprehensive Epilepsy Center, New York, USA.

Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were invited to enroll in this long-term open-label extension (OLE) trial, GWPCARE5 (NCT02224573). We present the final analysis of safety and efficacy outcomes from GWPCARE5.

中文翻译：

Lennox-Gastaut 综合征患者添加大麻二酚的长期安全性和有效性：长期开放标签扩展试验的结果

Lennox-Gastaut 综合征 (LGS) 是一种癫痫性脑病，通常难以治疗。两项随机对照试验 (RCT) 证明了附加大麻二酚 (CBD) 治疗与 LGS 相关的癫痫发作的有效性和安全性。完成 RCT 的患者被邀请参加这项长期开放标签扩展 (OLE) 试验，GWPCARE5 (NCT02224573)。我们介绍了 GWPCARE5 的安全性和有效性结果的最终分析。

更新日期：2021-08-29

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>